Abstract: Disclosed are compositions comprising a YAP1/WWRT1 inhibiting agent and a glutaminase inhibiting agent and methods of their use. Disclosed herein are therapeutic particles comprising a biocompatible polymer, a YAP1/WWRT1 inhibiting agent, and a glutaminase inhibiting agent. In one aspect, disclosed herein are methods of treating a pulmonary disease in a subject in need of such treatment comprising administering the therapeutic particle to the subject.

Abstract: The system can include a set of joints, a controller, and a model engine; and can optionally include a support structure and an end effector. Joints can include: a motor, a transmission mechanism, an input sensor, and an output sensor. The system can enable articulation of the plurality of joints.

Abstract: The present disclosure relates to probiotics and probiotic compositions having modified energy metabolisms (e.g., modifying, metabolizing, or storing energy molecules, e.g., lipids, before the energy molecules are absorbed by a host subject), and thus modulating the absorption of the energy molecules by the host subject. The present disclosure also relates to methods of making such probiotics and probiotic compositions. The present disclosure further relates to methods of regulating (e.g., maintaining or reducing) body weight in a subject (e.g., a subject having a healthy BMI, a subject having an overweight BMI, a subject having an obese BMI), using the probiotics and probiotic compositions disclosed herein.

Abstract: The present disclosure relates to probiotics and probiotic compositions having modified energy metabolisms (e.g., modifying, metabolizing, or storing energy molecules, e.g., lipids, before the energy molecules are absorbed by a host subject), and thus modulating the absorption of the energy molecules by the host subject. The present disclosure also relates to methods of making such probiotics and probiotic compositions. The present disclosure further relates to methods of regulating (e.g., maintaining or reducing) body weight in a subject (e.g., a subject having a healthy BMI, a subject having an overweight BMI, a subject having an obese BMI), using the probiotics and probiotic compositions disclosed herein.

Abstract: The present disclosure relates to probiotics and probiotic compositions having modified carbohydrate metabolism (e.g., modifying or metabolizing carbohydrates, or reduced glucose production), and thus regulating the absorption of the carbohydrates by the host subject. The present disclosure also relates to methods of making the probiotics and probiotic compositions. The present disclosure further relates to methods of regulating body weight in a subject, and methods of treating carbohydrate metabolism disorder, using the probiotics and probiotic compositions disclosed herein.

Abstract: In some examples, the disclosure describes a film including a rare-earth element-doped metal stannate exhibiting an electrical conductivity of at least about 104 S/cm at room temperature, where the metal includes at least one of barium, strontium, calcium, or zinc.

Abstract: The present disclosure relates to probiotics and probiotic compositions having modified energy metabolisms (e.g., modifying, metabolizing, or storing energy molecules, e.g., lipids, before the energy molecules are absorbed by a host subject), and thus modulating the absorption of the energy molecules by the host subject. The present disclosure also relates to methods of making such probiotics and probiotic compositions. The present disclosure further relates to methods of regulating (e.g., maintaining or reducing) body weight in a subject (e.g., a subject having a healthy BMI, a subject having an overweight BMI, a subject having an obese BMI), using the probiotics and probiotic compositions disclosed herein.

Abstract: Disclosed are compositions comprising a YAP1/WWRT1 inhibiting agent and a glutaminase inhibiting agent and methods of their use. Disclosed herein are therapeutic particles comprising a biocompatible polymer, a YAP1/WWRT1 inhibiting agent, and a glutaminase inhibiting agent. In one aspect, disclosed herein are methods of treating a pulmonary disease in a subject in need of such treatment comprising administering the therapeutic particle to the subject.

Abstract: In some examples, the disclosure describes a film including a rare-earth element-doped metal stannate exhibiting an electrical conductivity of at least about 104 S/cm at room temperature, where the metal includes at least one of barium, strontium, calcium, or zinc.

Abstract: Embodiments of the present disclosure provide for arrays, systems, and methods analyzing cells, methods of making arrays, and the like.

Abstract: Embodiments of the present disclosure provide for arrays, systems, and methods analyzing cells, methods of making arrays, and the like.

Abstract: Embodiments of the present disclosure provide for arrays, systems, and methods for the analyzing cells, methods of making arrays, and the like.

Abstract: Embodiments of the present disclosure provide for arrays, systems, and methods analyzing cells, methods of making arrays, and the like.

Abstract: Embodiments of the present disclosure provide for arrays, systems, and methods for the analyzing cells, methods of making arrays, and the like.